The US Food and Drug Administration (FDA) has updated the Emergency Use Authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir and ritonavir), permitting pharmacists to prescribe the therapy to patients who are eligible.

Paxlovid is authorised by the FDA to treat mild-to-moderate Covid-19 in adults and paediatric patients aged 12 years and above, who are at increased disease progression risk, including hospitalisation or mortality. 

The revised EUA has certain limitations to guarantee suitable assessment of the patient and prescribing of the oral antiviral. 

Patients who test positive for Covid-19 should initially seek care from their regular health care provider or locate a Test-to-Treat site in their region. 

This aids state-licenced pharmacists in prescribing Paxlovid with some limitations.

Those patients, who prefer receiving Paxlovid at locations where state-licensed pharmacists’ prescribing is available, should provide electronic or printed health records that are under 12 months old.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These patients should also make available a list of medications they are receiving, which will aid the pharmacist to screen for drugs that can have serious interactions with Paxlovid.

If sufficient data is not available, the pharmacist should refer them for clinical assessment with a physician, advanced practice registered nurse or physician assistant who can prescribe treatments.

FDA Center for Drug Evaluation and Research director Patrizia Cavazzoni said: “The FDA recognises the important role pharmacists have played and continue to play in combatting this pandemic. 

“Since Paxlovid must be taken within five days after symptoms begin, authorising state-licensed pharmacists to prescribe Paxlovid could expand access to timely treatment for some patients who are eligible to receive this drug for the treatment of Covid-19.”